Canary Bio participates in 'Bio-Europe'... Discussing partnerships with global pharmaceutical companies
[Asia Economy Reporter Jang Hyowon] Canaria Bio announced on the 12th that it will participate in Bio-Europe, held in Leipzig, Germany from the 24th to the 26th, to discuss strategic partnerships with global pharmaceutical companies.
Canaria Bio CEO Nahanik said, “Since this global Phase 3 clinical trial has been conducted for two years and interim results will be announced by mid-next year, the time has come to actively engage in partnership discussions with pharmaceutical companies.”
CEO Nahanik also stated, “Currently, it is difficult to achieve a progression-free survival (PFS) of over 12 months with only the standard treatments Paclitaxel and Carboplatin, and after the interim results in mid-next year, the probability of success is expected to increase significantly over time,” emphasizing, “Therefore, as time passes, the likelihood of concluding partnerships under better conditions is increasing.”
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- Ebola Outbreak With No Vaccine or Treatment Sparks Fears: "One American Infected"
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Canaria Bio plans to distribute Oregovomab through partnerships in all markets except the United States. In the U.S., the company aims to achieve an operating profit margin of over 50% through direct distribution. The global pharmaceutical market research firm Evaluate Pharma has predicted that Oregovomab could generate sales of up to 6 trillion KRW in the U.S.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
